with a relatively long history of a localised tumour, usually on the sole of the foot, with no metastases. Group 2 (48%) included patients with a primary lesion with regional or distant metastases and a short clinical history. Group 3 (12%) consisted of patients presenting with metastatic melanoma in whom no primary lesion could be found. There were no distinguishing histological features among the three groups, and the authors suggested that a difference might exist in the host response to this tumour. Lewis (1967) also demonstrated an in vitro cytotoxic effect of autologous serum against melanoma cells of Group 1 but not Group 2 patients, suggesting possible immunological differences.
The present study was undertaken to examine the immunologic status in the patient with localised and metastatic malignant melanoma, and to determine if defective immune mechanisms might be related to the occurrence of tumour metastasis. To this end, a study of cellular and humoral immunity in 19 Ugandan patients with malignant melanoma was performed.
MATERIAL AND METHODS
All patients with a histopathological diagnosis of malignant melanoma admitted to the Lymphoma Treatment Centre or the surgical wards of the New Mulago Hospital, Kampala, Uganda, between January 1968 and January 1969 were studied. The patients were classified into one of the 3 clinical groups mentioned above. All patients were studied before surgery or the administration of any cytotoxic agents.
Cellular immunity
Dinitrochlorobenzene (DNCB)t and 5 common skin test antigens were used to evaluate the delayed hypersensitivity response. A sensitising dose of 2000 ,tg. of DNCB in 0 1 ml. of acetone was applied to the medial aspect of the right upper arm within a 2 cm. polyethylene ring, allowed to evaporate, and covered with an adhesive bandage for one week (Brown et al., 1967 Lymphocyte transformation with phytohaemagglutinin-M (PHA) (Difco, Detroit, Mich.) in vitro was determined by the following procedure. Twenty ml. of heparinised blood was allowed to settle at room temperature for 1-2 hours, and the leukocytes were counted and adjusted to a final concentration of 106/ml. with Hyland agammaglobulinaemic newborn calf serum. One ml. of leukocyte suspension was incubated with 2 ml. of minimal essential media containing 100 units of streptomycin, 100 units of penicillin and 50 jig. of glutamine per ml. (Flow Laboratories, Rockville, Md.). Cultures were prepared in duplicate with and without 0-05 ml. of PHA, and incubated for 4 days at 370 C. Cultures were harvested by centrifugation at 1500 r.p.m. for 8 minutes in an International Centrifuge No. 269 head, fixed in a freshly prepared mixture of 1: 9 glacial acetic acid and 9500 alcohol for 10 minutes and recentrifuged. The cells were pipetted on slides, air dried, and stained with Giemsa's stain. For each culture 300 cell differential counts of normal lymphocytes, lymphoblastoid lymphocytes, mitoses and macrophages were performed and the percentage of transformed lymphocytes were calculated from the ratio of lymphoblastoid and mitotic cells to the total lymphoid cells counted. Average percentages of the two unstimulated and PHAstimulated cultures were calculated separately.
Humoral immunity
Antibody response to Vi antigen* was measured following the intramuscular administration of 100 ,tg. of antigen. Pre-immunisation and 14-day postimmunisation serum was collected, stored at 20°C., and serum titres were determined in two-fold dilutions by a haemagglutination technique (Landy and Lamb, 1953) .
Immunoglobulin levels were measured in duplicate by the gel diffusion method of Fahey and McKelvey (1965) , using Hyland antibody-agar plates. Assays were performed at the National Cancer Institute, Bethesda, Md., on specimens of serum collected and stored at -20°C. and shipped frozen from Kampala.
Controls
Twelve adult males who were hospitalised for trauma served as controls for the Vi All patients but 2 (cases 18 and 19) had a primary lesion on the sole of the foot; the two exceptions had groin metastases without detectable primary lesions, although case 19 had a dark black spot on the heel which may have been a regressed primary tumour. For purposes of this study Group 3 patients are considered part of Group 2, as they manifest metastatic disease. In a number of instances intervening circumstances (death, inadvertent discharge, or running away from hospital) prevented the completion of assays requiring a 2 week interval (DNCB sensitisation and Vi antibody titre). Per cent lymphocyte transformation with PHA in vitro is shown in Fig. 1 , and reveals normal values in the 17 patients tested.
Antibody response to Vi antigen in 13 patients who had pre-immunisation titres of less than 1: 8 is shown in Fig. 2 . The antibody titres, expressed as increments in tube dilution, are comparable in both clinical groups, and are within the normal range. Some degree of depressed immunologic reactivity has been observed in patients with other types of advanced cancer (Solowey and Rapaport, 1965; Lamb et al., 1962; Krant et al., 1968) . This phenomenon may be related to many factors, including the type and extent of cancer, the age of the patient, the nature of the antigenic stimulus, involvement of lymphatic tissue by tumour, chemotherapy, radiotherapy, intercurrent or debilitating disease, and nutritional status. The present study revealed normal immune responses in all patients with melanoma, even though some had metastatic disease. Thus all patients are presumably capable of initiating an anti-tumour immunologic response, and other factors such as tumour-specific antigenicity should be investigated to explain the containment or spread of malignant melanoma.
SUMMARY
The natural history of malignant melanoma in Uganda suggests differences in the immune status of the host in the localised (Group 1) and disseminated (Group 2) condition. Cellular and humoral immune responses were evaluated in this study and were found to be normal in both clinical groups. Therefore, generalised non-specific suppression of immune mechanisms cannot explain these clinical differences.
